Negative NICE draft guidance for Lutathera

3 August 2017

UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has today published draft guidance which does not recommend French molecular nuclear medicine specialist Advanced Accelerator Applications’ (Nasdaq: AAAP) Lu-177 dotatate (trade name Lutathera) for treating neuroendocrine tumors of gastrointestinal and pancreatic origin.

Lu-177 dotatate works on progressive neuroendocrine tumors that cannot be operated on or have spread. Neuroendocrine tumors can be found in several parts of the body, but the most common areas are the pancreas, gastrointestinal tissue and the lungs. Lu-177 is administered intravenously and it is a radionuclide, which attaches to the surface of the tumor and emits radiation to destroy it.

The cost-effectiveness estimates for Lu-177 dotatate were much higher than the £20,000 ($26,440)- £30,000 ($39,660) per quality adjusted life year (QALY) normally considered as cost-effective by the NICE. The treatment did not meet the end of life criteria considered by the NICE.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK